Common use of Sublicense Fees Clause in Contracts

Sublicense Fees. Licensee agrees to pay to Licensor sublicense fees as follows: (1) of any license fees and milestone payments (but excluding royalty payments) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, for Licensed Products if the sublicense is for a Single Agent Products and such sublicense is entered prior to the initiation of a Phase II Clinical Trial. (2) of any license fees and milestone payments (but excluding royalty payments) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, if the sublicense involves only a Combination Product(s) and such sublicense is entered prior to the initiation of a Phase II Clinical Trial. (3) of any license fees and milestone payments (but excluding royalty payments) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, if the sublicense involves only a Single Agent Product(s) and such sublicense is entered after the initiation of a Phase II Clinical Trial. (4) of any license fees and milestone payments (but excluding royalties) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, if the sublicense involves only a Combination Product(s) and such sublicense is entered after the initiation of a Phase II Clinical Trial.

Sublicense Fees. Licensee agrees to pay to Licensor sublicense fees as follows: (1) of any license fees and milestone payments payment (but excluding royalty payments) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, for Licensed Products if the sublicense is for a Single Agent Products Product(s) and such sublicense is entered prior to into within ** of the initiation of a Phase II Clinical TrialEffective Date. (2) of any license fees and milestone payments (but excluding royalty payments) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, if the sublicense involves only a Combination Product(s) and such sublicense is entered prior to into within ** of the initiation of a Phase II Clinical TrialEffective Date. (3) of any license fees and milestone payments (but excluding royalty payments) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, if the sublicense involves only a Single Agent Product(s) or Combination Product(s) and such sublicense is entered after into from ** to ** of the initiation of a Phase II Clinical TrialEffective Date. (4) of any license fees and milestone payments (but excluding royalties) paid to Licensee by any Sublicensee minus the corresponding minimum license fee or milestone payment previously paid to Licensor by Licensee, if any, if the sublicense involves only a Single Agent Product(s) or Combination Product(s) and such sublicense is entered into later than ** after the initiation of a Phase II Clinical TrialEffective Date.